Daniel M. Jones

4.6k citations

71 papers · 3.3k · 3 hit papers · h-index 26

Impact in

Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Hepatology top 2%
- Hepatitis C virus research

Papers in

Molecular Biology 18
- Peroxisome Proliferator-Activated Receptors 4
Infectious Diseases 14
- SARS-CoV-2 and COVID-19 Research 8

Co-authors: John McLauchlan (4 shared papers)Lan Bo Chen (1 shared paper)Christopher D.�M. Fletcher (1 shared paper)Elisabetta Mueller (1 shared paper)Samuel Singer (1 shared paper)Frederick J. King (1 shared paper)Bruce M. Spiegelman (1 shared paper)Sylvia A. Holden (1 shared paper)
Journals: Journal of Clinical Oncology (6 papers)Cell Reports (4 papers)Blood (3 papers)Scientific Reports (3 papers)Modern Pathology (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Daniel M. Jones

68 papers receiving 3.3k citations

Daniel M. Jones's Hit Papers

align trajectories log scale

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants 2023 · 102 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Cell Reports
2022 Cell Host & Microbe
1998 Nature Medicine

Peers

Countries citing papers authored by Daniel M. Jones

Since Specialization

Citations

This map shows the geographic impact of Daniel M. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Jones more than expected).

Fields of papers citing papers by Daniel M. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel M. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Jones. The network helps show where Daniel M. Jones may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel M. Jones, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel M. Jones Line = papers co-authored together Daniel M. Jones links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 71 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Differentiation and reversal of malignant changes in colon cancer through PPARγ Nature Medicine ·Pasha Sarraf, Elisabetta Mueller, Daniel M. Jones, Frederick J. King, Daniel J. DeAngelo, Jeffrey B. Partridge, Sylvia A. Holden, Lan Bo Chen, Samuel Singer, Christopher D.�M. Fletcher, Bruce M. Spiegelman Hit paper breakdown →	1998	867
2	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia Journal of Clinical Oncology ·Farhad Ravandi, Jörge E. Cortes, Daniel M. Jones, Stefan Faderl, Guillermo Garcia‐Manero, Marina Konopleva, Susan O’Brien, Zeev Estrov, Gautam Borthakur, Deborah A. Thomas, Sherry R. Pierce, Mark Brandt, Anna Byrd, B. Nebiyou Bekele, Keith W. Pratz, Rajyalakshmi Luthra, Mark J. Levis, Michael Andreeff, Hagop M. Kantarjian	2010	282
3	Toremifene interacts with and destabilizes the Ebola virus glycoprotein Nature ·Yuguang Zhao, Jingshan Ren, Karl Harlos, Daniel M. Jones, Antra Zeltina, Thomas A. Bowden, Sergi Padilla‐Parra, Elizabeth E. Fry, David I. Stuart	2016	186
4	Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2 Cell Host & Microbe ·Panke Qu, John P. Evans, Julia N. Faraone, Yi-Min Zheng, Claire Carlin, Mirela Anghelina, Patrick Stevens, Soledad Fernández, Daniel M. Jones, Gerard Lozanski, Ashish R. Panchal, Linda J. Saif, Eugene M. Oltz, Kai Xu, Richard J. Gumina, Shan‐Lu Liu Hit paper breakdown →	2022	170
5	Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia Blood ·Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Daniel M. Jones, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, Jörge E. Cortes	2006	153
6	Precursor B-cell Lymphoblastic Lymphoma The American Journal of Surgical Pathology ·Pei Lin, Daniel M. Jones, David M. Dorfman, L. Jeffrey Medeiros	2000	116
7	The Hepatitis C Virus NS4B Protein Can trans -Complement Viral RNA Replication and Modulates Production of Infectious Virus Journal of Virology ·Daniel M. Jones, Arvind H. Patel, Paul Targett‐Adams, John McLauchlan	2008	115
8	Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants Cell Reports ·Panke Qu, Julia N. Faraone, John P. Evans, Yi-Min Zheng, Claire Carlin, Mirela Anghelina, Patrick Stevens, Soledad Fernández, Daniel M. Jones, Ashish R. Panchal, Linda J. Saif, Eugene M. Oltz, Baoshan Zhang, Tongqing Zhou, Kai Xu, Richard J. Gumina, Shan‐Lu Liu Hit paper breakdown →	2023	102
9	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations Blood ·Elias Jabbour, Daniel M. Jones, Hagop M. Kantarjian, Susan O’Brien, Constantine S. Tam, Charles Koller, Jan A. Burger, Gautam Borthakur, William G. Wierda, Jörge E. Cortes	2009	94
10	Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis Hepatology ·Ragunath Singaravelu, Ran Chen, Rodney K. Lyn, Daniel M. Jones, Shifawn O’Hara, Y Rouleau, Jenny Cheng, Prashanth Srinivasan, Neda Nasheri, Rodney S. Russell, D. Lorne Tyrrell, John Paul Pezacki	2013	93
11	Hepatitis C Virus: Assembly and Release of Virus Particles Journal of Biological Chemistry ·Daniel M. Jones, John McLauchlan	2010	89
12	CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma Journal of Investigative Dermatology ·Rakhshandra Talpur, Daniel M. Jones, Alvaro J. Alencar, Narin Apisarnthanarax, Kelly L. Herne, Ying Yang, Madeleine Duvic	2006	83
13	Astrocytes Resist HIV-1 Fusion but Engulf Infected Macrophage Material Cell Reports ·Rebecca A Russell, Jakub Chojnacki, Daniel M. Jones, Errin Johnson, Thao Do, Christian Eggeling, Sergi Padilla‐Parra, Quentin J. Sattentau	2017	72
14	MicroRNAs regulate the immunometabolic response to viral infection in the liver Nature Chemical Biology ·Ragunath Singaravelu, Shifawn O’Hara, Daniel M. Jones, Ran Chen, Nathan Taylor, Prashanth Srinivasan, Curtis Quan, Dominic G. Roy, Renske D.M. Steenbergen, Anil Kumar, Rodney K. Lyn, Dennis Özcelik, Y Rouleau, My-Anh Nguyen, Katey J. Rayner, Tom C. Hobman, David Tyrrell, Rodney S. Russell, John Paul Pezacki	2015	56
15	Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes Scientific Reports ·Rodney K. Lyn, Ragunath Singaravelu, Stacia Kargman, Shifawn O’Hara, Helen M. Chan, Renata M. Oballa, Zheng Huang, Daniel M. Jones, Andrew Ridsdale, Rodney S. Russell, Anthony W. Partridge, John Paul Pezacki	2014	56
16	Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers Hepatology ·Renske D.M. Steenbergen, Michael Joyce, Bradley Thomas, Daniel M. Jones, John Law, Rodney S. Russell, Michael Houghton, D. Lorne Tyrrell	2013	54
17	Mutation-Specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the Identification of a Newly Emerging Variant with Spike L452R Mutation Journal of Clinical Microbiology ·Huanyu Wang, Sophonie Jean, Richard Eltringham, John Madison, Pamela J. Snyder, Huolin Tu, Daniel M. Jones, Amy L. Leber	2021	50
18	Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response Journal of Clinical Oncology ·Hagop M. Kantarjian, Jianqin Shan, Daniel M. Jones, Susan O’Brien, Mary Beth Rios, Elias Jabbour, Jörge E. Cortes	2009	50
19	BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer Clinical Cancer Research ·Nitu Bansal, Monica Bartucci, Shamila Yusuff, Stephani A. Davis, Kathleen Flaherty, Eric Huselid, Michele Patrizii, Daniel M. Jones, Liangxian Cao, Nadiya Sydorenko, Young‐Choon Moon, H. Zhong, Daniel Medina, John E. Kerrigan, Mark N. Stein, Isaac Yi Kim, Thomas W. Davis, Robert S. DiPaola, Joseph Bertino, Hatem E. Sabaawy	2016	49
20	Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants Cell Reports ·Pei Li, Julia N. Faraone, Cheng Chih Hsu, Michelle Chamblee, Yi-Min Zheng, Claire Carlin, Joseph S. Bednash, Jeffrey C. Horowitz, Rama K. Mallampalli, Linda J. Saif, Eugene M. Oltz, Daniel M. Jones, Jiànróng Lǐ, Richard J. Gumina, Kai Xu, Shan‐Lu Liu	2024	42

About Daniel M. Jones

Daniel M. Jones is a scholar working on Molecular Biology, Infectious Diseases, Epidemiology, Hematology and Hepatology, having authored 71 papers that have together received 3.3k indexed citations. Recurring topics across this work include Hepatitis C virus research (10 papers), Hepatitis B Virus Studies (8 papers), SARS-CoV-2 and COVID-19 Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers), Eosinophilic Disorders and Syndromes (5 papers), Acute Myeloid Leukemia Research (5 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Peroxisome Proliferator-Activated Receptors (4 papers). The work is most often cited by research in Hematology (595 citations), Hepatology (350 citations), Infectious Diseases (635 citations), Cancer Research (492 citations) and Genetics (317 citations). Daniel M. Jones has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include John McLauchlan, Lan Bo Chen, Christopher D.�M. Fletcher, Elisabetta Mueller, Samuel Singer, Frederick J. King, Bruce M. Spiegelman, Sylvia A. Holden, Pasha Sarraf and Daniel J. DeAngelo. Their work appears in journals such as Journal of Clinical Oncology, Cell Reports, Blood, Scientific Reports and Modern Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Daniel M. Jones

Impact in

Papers in i

In The Last Decade

Daniel M. Jones

Daniel M. Jones's Hit Papers

Peers

Countries citing papers authored by Daniel M. Jones

Fields of papers citing papers by Daniel M. Jones

All Works

About Daniel M. Jones

Explore authors with similar magnitude of impact

Papers in